|
|
|
|
Zero Calcium Score Cannot Rule Out CAD in Symptomatic Patients
Contrary to current American Heart Association (AHA)/American College of Cardiology (ACC) guidelines, a new study shows that the absence of coronary calciuma calcium score of 0is not a reliable gatekeeper for ruling out patients with suspected coronary artery...
|
|
|
Promising New CTO Tools Await Clinical Validation
NEW YORKInnovative technologies specifically designed to improve percutaneous treatment of chronic total occlusions (CTOs)some in development for many yearsare starting to make progress toward clinical use, according to updates presented February 5, 2010,at the...
|
|
|
Vertebral Artery Stenting Shows Promise as Alternative to Surgery
In patients with symptomatic vertebral artery stenosis, stents are a safe, effective, and durable alternative to medical or open surgical therapy, according to a study published in the February 9, 2010, issue of the Journal of the American College of Cardiology...
|
|
|
Europe, North America Gaining CTO Experience But Attempt Rates Still Low
NEW YORKPercutaneous coronary intervention (PCI) for chronic total occlusions (CTOs) is an evolving field, with more and more operators willing to attempt the procedure.Despite this, undertreatment remains an issue, according to physicians who spoke about...
|
|
|
3D-Echocardiographic Guidance of Septal Defect Closure Interventions: Desirable or Essential?
_ 3D-Echocardiographic Guidance of Septal Defect Closure Interventions: Desirable or Essential?.
|
|
|
Is There a Clinical Need for Dedicated Bifurcation and Left Main Stents?
_ Is There a Clinical Need for Dedicated Bifurcation and Left Main Stents?.
|
|
|
The Emerging Role of Genetics in Predicting Individual Risk
_ The Emerging Role of Genetics in Predicting Individual Risk.
|
|
|
To Be, Rather Than to Appear
_ To Be, Rather Than to Appear.
|
|
|
St. Jude Medical Announces European Approval of Smaller, Higher Power ICD and CRT-D Devices with New Heart Fai
_ St.Jude Medical Announces European Approval of Smaller, Higher Power ICD and CRT-D Devices with New Heart Fai.
|
|
|
Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial For Treatment Of Recurrent
_ Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial For Treatment Of Recurrent.
|
